Drug Shortage Report for SODIUM CHLORIDE INJECTION, USP

Last updated on 2022-08-21 History
Report ID 165704
Drug Identification Number 02139510
Brand name SODIUM CHLORIDE INJECTION, USP
Common or Proper name SODIUM CHLORIDE INJECTION, USP
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) SODIUM CHLORIDE
Strength(s) 234MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 200 mL
ATC code B05XA
ATC description I.V. SOLUTION ADDITIVES
Reason for shortage Delay in shipping of the drug.
Anticipated start date
Actual start date 2022-08-01
Estimated end date 2022-08-21
Actual end date 2022-08-15
Shortage status Resolved
Updated date 2022-08-21
Company comments Fresenius Kabi Canada regrets to advise that due to shipping delays, we will be encountering a supply interruption on our Sodium Chloride Injection, USP 4mEq/mL Maxivial® 200 mL effective August 1, 2022 until August 21, 2022. Once available, this product will remain on allocation. Contract customers will be allocated 100% of historical monthly demand.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v5 2022-08-21 French Compare
v4 2022-08-21 English Compare
v3 2022-08-02 English Compare
v2 2022-07-29 French Compare
v1 2022-07-29 English Compare

Showing 1 to 5 of 5